ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,795
0,20%
Bitcoin
59 419,38
0,50%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ARS Pharmaceuticals Inc (SPRY)

  7. ARS Pharmaceuticals Inc (SPRY) Actualités

SPRY ARS Pharmaceuticals Inc

9,46
0,13 (1,39%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ARS Pharmaceuticals Inc SPRY NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,13 1,39% 9,46 00:21:22
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,35 8,94 9,51 9,46 9,33
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202415:01GLOBEARS Pharmaceuticals Submits Response for neffy® (epinephrine..
03/4/202415:01GLOBEARS Pharmaceuticals Submits Response to FDA Complete..
21/3/202421:05GLOBEARS Pharmaceuticals Provides Business Update and Reports..
07/3/202422:05GLOBEARS Pharmaceuticals Reviews Recent Clinical Updates and..
07/3/202418:56EDGAR2Form 8-K - Current report
06/3/202415:01GLOBEARS Pharmaceuticals to Participate in the Leerink Partners..
02/3/202402:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202403:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202418:08EDGAR2Form 144 - Report of proposed sale of securities
26/2/202415:01GLOBEARS Pharmaceuticals announces neffy® meets primary endpoints..
22/2/202415:01GLOBEARS Pharmaceuticals to Host Virtual neffy® Investor Day on..
20/2/202415:01GLOBEARS Pharma Announces Favorable Topline Results from Repeat..
05/2/202415:01GLOBEARS Pharmaceuticals to Present Positive Clinical Efficacy..
04/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202322:02EDGAR2Form 8-K - Current report
09/11/202322:00GLOBEARS Pharmaceuticals Reports Third Quarter 2023 Financial..
09/11/202317:02GLOBEARS Pharmaceuticals Announces Presentation of Clinical Data..
06/10/202315:57DJNARS Pharmaceuticals to Meet With FDA on Neffy Rejection
06/10/202315:03GLOBEARS Pharmaceuticals Announces Scheduling of a Type A Meeting..
03/10/202315:03GLOBESingle and Repeat Dose Clinical Study of neffy (epinephrine..
25/9/202322:17EDGAR2Form 8-K - Current report
20/9/202316:20DJNARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy..
20/9/202312:30DJNARS Pharmaceuticals Shares Sink Premarket as FDA Rejects..
20/9/202312:05EDGAR2Form 8-K - Current report
20/9/202304:49GLOBEFDA Issues Complete Response Letter for neffy® (epinephrine..
01/9/202322:15EDGAR2Form SC 13D/A - General statement of acquisition of..
10/8/202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:05EDGAR2Form 8-K - Current report
10/8/202322:00GLOBEARS Reports Second Quarter 2023 Financial Results and..
29/6/202303:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202322:32EDGAR2Form 8-K - Current report
20/6/202314:00GLOBEARS Pharmaceuticals Announces PDUFA Date Extension for..
15/5/202315:00GLOBEARS Pharmaceuticals Highlights Progress and Reports First..
12/5/202314:55DJNARS Pharmaceuticals Soar 68% in Premarket Trading as FDA..
12/5/202301:01GLOBEFDA Advisory Committee Votes in Support of Favorable..
09/5/202315:10GLOBEARS Pharmaceuticals Announces Availability of Briefing..

Dernières Valeurs Consultées

NASDAQ
SPRY
ARS Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés